Company: NCEL
Filing Date: 2025-11-14
Form Type: SCHEDULE 13D
Source: 0001213900-25-110759
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-11-14
Form: SCHEDULE 13D
Chunk 0
---
.97, for aggregate gross proceeds of $3.2 million. The Common Warrants have a term of five years and have an exercise price of $4.25 per share. Pursuant to the securities purchase agreement, the Issuer agreed to grant the investors the right to participate, in the aggregate, in up to fifty percent (50%) of future offerings for one year following the closing of the offering. In addition, the Issuer agreed to not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the securities purchase agreement closed on October 10, 2024. In connection with this securities purchase agreement, the Reporting Person purchased 189,012 Common Shares and common warrants to purchase 189,012 Common Shares, all with his personal funds. Following the Merger, such Common Shares and common warrants were adjusted per a 1-for-10 reverse split. 
 Merger Transaction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
 On November 4, 2024, NLS entered into an Agreement and Plan of Merger, as subsequently amended, with Kadimastem Ltd. ("Kadimastem"). The merger (the "Merger") was completed in 2025, pursuant to which NLS Pharmaceutics (Israel) Ltd., a wholly owned subsidiary of NLS, merged with and into Kadimastem, with Kadimastem continuing as the surviving company and a wholly owned subsidiary of NLS. Following the Merger, the combined company was renamed NewcelX, Ltd. ("NewcelX" or the "Issuer"). In connection with the Merger, each outstanding ordinary share of Kadimastem was exchanged for Common Shares in a final exchange ratio of 7.06 NLS common shares for each Kadimastem ordinary share, or 0.706 Common Shares in exchange for each Kadimastem ordinary share, reflecting the 1-for-10 reverse share split effected by NewCelX in connection with the Merger.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
 As a result of the Merger, the Reporting Person, who served as the Chief Scientific Officer and a director of Kadimastem, became the Chief Scientific Officer and a director of NewcelX. At the effective time of the Merger, 1,279,639 Kadimastem ordinary shares previously beneficially owned by the Reporting Person were converted into NLS common shares pursuant to the exchange ratio